NCT06670209Not yet recruitingPhase 1
A Phase I, Open-label, Fixed-sequence Study to Evaluate the Effect of Repeated Subcutaneous Injections of GZR18 Injection on the Pharmacokinetics of Oral Metformin Hydrochloride Tablets in Overweight/Obese Subjects
Gan and Lee Pharmaceuticals, USA0 sites32 target enrollmentStarted: October 30, 2024Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 32
- Primary Endpoint
- Cmax,ss
Study Overview
Brief Summary
This is a single-center, open-label, fixed-sequence phase I clinical study to evaluate the effect of multiple subcutaneous injections of GZR18 Injection on the pharmacokinetics of multiple oral doses of metformin hydrochloride tablets.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 50 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Overweight/obese Chinese subjects, who voluntarily sign the Informed Consent Form (ICF), can receive subcutaneous injection, fully understand the content, process and possible adverse reactions of the trial, and are able to follow the regulations on contraindications and restrictions specified in this protocol.
- •Male or female, 18 to 50 years of age at signing the ICF (both inclusive).
- •Weight ≥ 50 kg and body mass index (BMI) within 24-33 kg/m2 (both ends inclusive) at screening.
- •Subjects of childbearing potential with no birth plan from the signing of ICF to 3 months after the last dose, willingness to take effective contraceptive measures, and no plan for sperm or ovum donation. Females of childbearing potential must not be lactating and must have negative results of pregnancy tests at screening and Visit 2 (prior to enrollment).
Exclusion Criteria
- •Subjects with a previous or existing history of heart, liver, kidney, gastrointestinal tract, respiratory system, nervous system, psychiatric disease, malignant tumor and other diseases that are judged by the investigator to have an impact on pharmacokinetics and safety evaluation.
- •History or existing diseases that increase the risk of subjects, such as hypoglycaemia, acute or chronic pancreatitis, pancreatic injury, history of symptomatic gallbladder disease; cholelithiasis with high risk of acute biliary pancreatitis at screening (e.g., silt-like lithiasis, gallbladder ≤ 5 mm in diameter and bile duct stone, etc.).
- •Subjects with previous or existing diseases that significantly affect drug absorption, metabolism or excretion, such as history of active peptic ulcer or haemorrhage, inflammatory bowel disease, abnormal gastric emptying (such as gastric paresis or pyloric stenosis, gastric outlet obstruction), long-term use (continuous for ≥ 1 week) of drugs that affect gastrointestinal motility (including but not limited to domperidone, mosapride, macrolides).
- •Subjects with severe infection or unexplained infection within 4 weeks before screening.
- •Major surgery within 6 months prior to screening, or scheduled surgery or hospitalization during the study.
- •History of drug abuse prior to screening; or positive results for drug abuse at screening.
- •Subjects who used nicotine-containing products within 3 months prior to screening or are screened positive for nicotine in urine.
- •Other factors that make subjects unqualified to participate in this trial as judged by the Investigator.
Arms & Interventions
Treatment arm
Experimental
Intervention: GZR18 and metformin (Drug)
Outcomes
Primary Outcomes
Cmax,ss
Time Frame: 24 hours
AUC0-tau
Time Frame: 24 hours
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Completed
Phase 1
Study the Effect of Omeprazole on AB-106 PharmacokineticsPharmacokinetic StudyNCT05609929Nuvation Bio Inc.24
Completed
Phase 1
ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy ParticipantsType 2 Diabetes MellitusNCT06293742Eccogene48
Completed
Phase 1
The Effect of Reduced Liver Function on Selatogrel PharmacokineticsHealthy SubjectsHepatic ImpairmentNCT04406896Viatris Innovation GmbH24
Completed
Phase 1
A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic ImpairmentHepatic ImpairmentNCT03713242Idorsia Pharmaceuticals Ltd.32
Completed
Phase 1
Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-MD1003 in Healthy Male SubjectsHealthy VolunteersNCT04223232MedDay Pharmaceuticals SA6